Oncolytics Biotech Inc. leads the precision medicine market with $69.16 billion growth.
ByAinvest
Monday, Jan 12, 2026 10:43 am ET1min read
CGON--
ONCY--
ZNTL--
The oncology landscape is expected to experience significant growth, driven by the integration of genotype-directed treatment pathways into standard medical practice. The precision medicine market is projected to expand from $138.67 billion in 2026 to over $537.17 billion by 2035. Oncolytics Biotech Inc. (NASDAQ: ONCY), CG Oncology (NASDAQ: CGON), Zentalis Pharmaceuticals (NASDAQ: ZNTL), ArriVent BioPharma (NASDAQ: AVBP), and PDS Biotechnology (NASDAQ: PDSB) are strategic players in this high-velocity regulatory phase, fueled by the growth of the orphan drug market from $216.66 billion in 2025 to $687.47 billion by 2032.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet